What the Evidence Says About Medicinal Cannabis in Australia
A review of therapeutic cannabis evidence found limited but possible clinical uses for multiple sclerosis spasticity, cancer-related nausea, cancer pain, and HIV neuropathy, while emphasizing the need for regulatory safeguards.
Quick Facts
What This Study Found
This review examined the clinical evidence for medicinal cannabis and its derivatives in Australia's regulatory context. Possible clinical indications included spasticity and pain in multiple sclerosis, chemotherapy-induced nausea, cancer pain, and HIV neuropathy.
However, the review emphasized that evidence was limited, often reflected subjective rather than objective outcomes, and was not conclusive for any indication. At the time, nabiximols (Sativex) was the only cannabinoid on Australia's therapeutic goods register, and cannabidiol was being considered for scheduling.
The review stressed that introducing cannabinoids therapeutically should be supported by regulatory and educational frameworks that minimize risks to patients and the community.
Key Numbers
One cannabinoid product on Australian register (nabiximols); CBD recommended for Schedule 4; Regulator of Medicinal Cannabis Bill 2014 under consideration
How They Did This
Narrative review published in Australian Prescriber, examining clinical evidence for medicinal cannabis and the regulatory landscape in Australia as of 2015.
Why This Research Matters
This review captured a pivotal moment in Australian medical cannabis policy, when legislative frameworks were being developed. It provided clinicians with a balanced evidence summary while acknowledging the gap between public enthusiasm and clinical proof.
The Bigger Picture
Australia went on to establish a medicinal cannabis access scheme. This review represents the evidence base that informed early policy decisions, highlighting how limited the data was even as the policy moved forward.
What This Study Doesn't Tell Us
Brief overview rather than systematic review. Focused on the Australian regulatory context. Evidence quality for most indications was described as limited and not conclusive.
Questions This Raises
- ?Has the evidence base for medicinal cannabis strengthened since 2015?
- ?What has Australia's experience been with regulated medicinal access?
- ?Are patient-reported subjective benefits sufficient to justify therapeutic use?
Trust & Context
- Key Stat:
- Evidence described as limited and not conclusive for any indication
- Evidence Grade:
- Brief narrative review summarizing available evidence for an Australian clinical audience. Useful for policy context but not a comprehensive evidence synthesis.
- Study Age:
- Published in 2015. Australia has since implemented a medicinal cannabis access scheme, and additional evidence has accumulated.
- Original Title:
- Medicinal cannabis.
- Published In:
- Australian prescriber, 38(6), 212-5 (2015)
- Authors:
- Murnion, Bridin(4)
- Database ID:
- RTHC-01022
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is medicinal cannabis proven to work?
As of this 2015 review, evidence was described as limited and not conclusive for any specific indication. The strongest, though still limited, support was for MS spasticity, chemotherapy nausea, cancer pain, and HIV neuropathy.
What is nabiximols?
Nabiximols (brand name Sativex) is a mouth spray containing THC and CBD. It was the only cannabinoid on Australia's therapeutic register at the time, used primarily for MS spasticity and pain.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- medical-card-worth-it-2026-benefits-costs
Cite This Study
https://rethinkthc.com/research/RTHC-01022APA
Murnion, Bridin. (2015). Medicinal cannabis.. Australian prescriber, 38(6), 212-5.
MLA
Murnion, Bridin. "Medicinal cannabis.." Australian prescriber, 2015.
RethinkTHC
RethinkTHC Research Database. "Medicinal cannabis." RTHC-01022. Retrieved from https://rethinkthc.com/research/murnion-2015-medicinal-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.